Cargando…

E2 Partner Tunes the Ubiquitylation Specificity of Arkadia E3 Ubiquitin Ligase

SIMPLE SUMMARY: Ubiquitin-mediated proteasomal degradation is a fundamental and tightly coordinated process that controls the cellular concentration of proteins. E3 ubiquitin ligases are responsible for substrate recognition, and their deregulation is associated with various diseases, most notably,...

Descripción completa

Detalles Bibliográficos
Autores principales: Delegkou, Georgia N., Birkou, Maria, Fragkaki, Nefeli, Toro, Tamara, Marousis, Konstantinos D., Episkopou, Vasso, Spyroulias, Georgios A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954413/
https://www.ncbi.nlm.nih.gov/pubmed/36831384
http://dx.doi.org/10.3390/cancers15041040
_version_ 1784894111284723712
author Delegkou, Georgia N.
Birkou, Maria
Fragkaki, Nefeli
Toro, Tamara
Marousis, Konstantinos D.
Episkopou, Vasso
Spyroulias, Georgios A.
author_facet Delegkou, Georgia N.
Birkou, Maria
Fragkaki, Nefeli
Toro, Tamara
Marousis, Konstantinos D.
Episkopou, Vasso
Spyroulias, Georgios A.
author_sort Delegkou, Georgia N.
collection PubMed
description SIMPLE SUMMARY: Ubiquitin-mediated proteasomal degradation is a fundamental and tightly coordinated process that controls the cellular concentration of proteins. E3 ubiquitin ligases are responsible for substrate recognition, and their deregulation is associated with various diseases, most notably, cancer. The E3 ligase Arkadia (RNF111) targets for proteasomal degradation negative regulators of the TGF-β SMAD2/3 signaling pathway and poly-SUMOylated proteins, e.g., promyelocytic leukemia protein. Herein, we provide valuable insights into the interaction and function of Arkadia with its physiological E2 partners, UbcH5Β and UbcH13, as well as UbcH7. Specifically, we identify key amino acid residues on these E2 enzymes and Arkadia that are essential for their pairing and control of the enzymatic activity of Arkadia in ubiquitylation machinery. Our findings enrich the current knowledge on the pivotal components of the ubiquitylation system and can be the basis for future drug development. ABSTRACT: Arkadia (RNF111) is a positive regulator of the TGF-β signaling that mediates the proteasome-dependent degradation of negative factors of the pathway. It is classified as an E3 ubiquitin ligase and a SUMO-targeted ubiquitin ligase (STUBL), implicated in various pathological conditions including cancer and fibrosis. The enzymatic (ligase) activity of Arkadia is located at its C-terminus and involves the RING domain. Notably, E3 ligases require E2 enzymes to perform ubiquitylation. However, little is known about the cooperation of Arkadia with various E2 enzymes and the type of ubiquitylation that they mediate. In the present work, we study the interaction of Arkadia with the E2 partners UbcH5B and UbcH13, as well as UbcH7. Through NMR spectroscopy, we found that the E2–Arkadia interaction surface is similar in all pairs examined. Nonetheless, the requirements and factors that determine an enzymatically active E2–Arkadia complex differ in each case. Furthermore, we revealed that the cooperation of Arkadia with different E2s results in either monoubiquitylation or polyubiquitin chain formation via K63, K48, or K11 linkages, which can determine the fate of the substrate and lead to distinct biological outcomes.
format Online
Article
Text
id pubmed-9954413
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-99544132023-02-25 E2 Partner Tunes the Ubiquitylation Specificity of Arkadia E3 Ubiquitin Ligase Delegkou, Georgia N. Birkou, Maria Fragkaki, Nefeli Toro, Tamara Marousis, Konstantinos D. Episkopou, Vasso Spyroulias, Georgios A. Cancers (Basel) Article SIMPLE SUMMARY: Ubiquitin-mediated proteasomal degradation is a fundamental and tightly coordinated process that controls the cellular concentration of proteins. E3 ubiquitin ligases are responsible for substrate recognition, and their deregulation is associated with various diseases, most notably, cancer. The E3 ligase Arkadia (RNF111) targets for proteasomal degradation negative regulators of the TGF-β SMAD2/3 signaling pathway and poly-SUMOylated proteins, e.g., promyelocytic leukemia protein. Herein, we provide valuable insights into the interaction and function of Arkadia with its physiological E2 partners, UbcH5Β and UbcH13, as well as UbcH7. Specifically, we identify key amino acid residues on these E2 enzymes and Arkadia that are essential for their pairing and control of the enzymatic activity of Arkadia in ubiquitylation machinery. Our findings enrich the current knowledge on the pivotal components of the ubiquitylation system and can be the basis for future drug development. ABSTRACT: Arkadia (RNF111) is a positive regulator of the TGF-β signaling that mediates the proteasome-dependent degradation of negative factors of the pathway. It is classified as an E3 ubiquitin ligase and a SUMO-targeted ubiquitin ligase (STUBL), implicated in various pathological conditions including cancer and fibrosis. The enzymatic (ligase) activity of Arkadia is located at its C-terminus and involves the RING domain. Notably, E3 ligases require E2 enzymes to perform ubiquitylation. However, little is known about the cooperation of Arkadia with various E2 enzymes and the type of ubiquitylation that they mediate. In the present work, we study the interaction of Arkadia with the E2 partners UbcH5B and UbcH13, as well as UbcH7. Through NMR spectroscopy, we found that the E2–Arkadia interaction surface is similar in all pairs examined. Nonetheless, the requirements and factors that determine an enzymatically active E2–Arkadia complex differ in each case. Furthermore, we revealed that the cooperation of Arkadia with different E2s results in either monoubiquitylation or polyubiquitin chain formation via K63, K48, or K11 linkages, which can determine the fate of the substrate and lead to distinct biological outcomes. MDPI 2023-02-07 /pmc/articles/PMC9954413/ /pubmed/36831384 http://dx.doi.org/10.3390/cancers15041040 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Delegkou, Georgia N.
Birkou, Maria
Fragkaki, Nefeli
Toro, Tamara
Marousis, Konstantinos D.
Episkopou, Vasso
Spyroulias, Georgios A.
E2 Partner Tunes the Ubiquitylation Specificity of Arkadia E3 Ubiquitin Ligase
title E2 Partner Tunes the Ubiquitylation Specificity of Arkadia E3 Ubiquitin Ligase
title_full E2 Partner Tunes the Ubiquitylation Specificity of Arkadia E3 Ubiquitin Ligase
title_fullStr E2 Partner Tunes the Ubiquitylation Specificity of Arkadia E3 Ubiquitin Ligase
title_full_unstemmed E2 Partner Tunes the Ubiquitylation Specificity of Arkadia E3 Ubiquitin Ligase
title_short E2 Partner Tunes the Ubiquitylation Specificity of Arkadia E3 Ubiquitin Ligase
title_sort e2 partner tunes the ubiquitylation specificity of arkadia e3 ubiquitin ligase
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9954413/
https://www.ncbi.nlm.nih.gov/pubmed/36831384
http://dx.doi.org/10.3390/cancers15041040
work_keys_str_mv AT delegkougeorgian e2partnertunestheubiquitylationspecificityofarkadiae3ubiquitinligase
AT birkoumaria e2partnertunestheubiquitylationspecificityofarkadiae3ubiquitinligase
AT fragkakinefeli e2partnertunestheubiquitylationspecificityofarkadiae3ubiquitinligase
AT torotamara e2partnertunestheubiquitylationspecificityofarkadiae3ubiquitinligase
AT marousiskonstantinosd e2partnertunestheubiquitylationspecificityofarkadiae3ubiquitinligase
AT episkopouvasso e2partnertunestheubiquitylationspecificityofarkadiae3ubiquitinligase
AT spyrouliasgeorgiosa e2partnertunestheubiquitylationspecificityofarkadiae3ubiquitinligase